Available Technologies

Browse Penn-owned technologies available for licensing.


Novel uses of androgen receptor inhibitors in cancer

Repurposing of androgen receptors inhibitors for prostate cancer treatment to treat other cancer in males such as melanoma.

For many cancer types, women have lower incidence and better outcomes than men. The role of sex steroid hormones, such as estrogen and testosterone, has been studied in reproductive organ cancers such as prostate and breast cancer, but not in other non-androgen (AR)-driven cancers. Recent studies have shown that testosterone promotes cancer cell proliferation. 



Inhibiting testosterone-induced tumor growth as a new therapeutic approach for non-AR-driven cancer. 


Technology Overview: 

Dr. Ridky and colleagues demonstrated that testosterone promotes cancer cell proliferation through a non-AR-dependent mechanism.  Four existing FDA-approved androgen receptor inhibitors, flutamide, bicalutamide, enzalutamide, and apalutamide, are inhibiting the proliferation of different cancer cell lines, from non-reproductive non-AR expressing tissues. Hence these therapeutics may have a way broader therapeutic effect than earlier contemplated. 

Both bicalutamide (CDX) and enzalutamide (ENZ) completely block testosterone-induced proliferation of melanoma cell lines.


Tumor growth in SCID male mice bearing WM46-derived subcutaneous tumors was inhibited by Apalutamide (20mg/kg/day via oral gavage).



Enhance effectiveness of current cancer therapy treatment using already approved drugs 


Stage of Development: 

In Vivo POC


Intellectual Property: 

Patent application filed


Desired Partnerships: 

Sponsored research and licensing


Docket # 20-9153


Download pdf


Patent Information:
For Information, Contact:
Viviane Martin
University of Pennsylvania
Todd Ridky
Cristina Aguirre Portol├ęs
Christopher Natale